M02 Stock Overview
A life-science company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
iZafe Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0082 |
| 52 Week High | SEK 0.029 |
| 52 Week Low | SEK 0.006 |
| Beta | 0.41 |
| 11 Month Change | -2.38% |
| 3 Month Change | -21.15% |
| 1 Year Change | -72.11% |
| 33 Year Change | -91.66% |
| 5 Year Change | -96.60% |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| M02 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -12.8% | -2.0% | -0.2% |
| 1Y | -72.1% | -32.3% | 7.8% |
Return vs Industry: M02 underperformed the German Healthcare Services industry which returned -32.4% over the past year.
Return vs Market: M02 underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| M02 volatility | |
|---|---|
| M02 Average Weekly Movement | 33.2% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: M02's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: M02's weekly volatility has increased from 23% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 7 | Anders Segerstrom | www.izafe.se |
iZafe Group AB (publ), a life-science company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated drug dispenser that handles dose bags, facilitates and enables independent medication, and reminds and alerts if the current dose is not taken at the right time. It serves consumers, and public and private-sector care providers in Sweden, the Nordic region, and internationally.
iZafe Group AB (publ) Fundamentals Summary
| M02 fundamental statistics | |
|---|---|
| Market cap | €4.76m |
| Earnings (TTM) | -€2.76m |
| Revenue (TTM) | €543.40k |
8.8x
P/S Ratio-1.7x
P/E RatioIs M02 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M02 income statement (TTM) | |
|---|---|
| Revenue | SEK 6.29m |
| Cost of Revenue | SEK 6.38m |
| Gross Profit | -SEK 95.00k |
| Other Expenses | SEK 31.89m |
| Earnings | -SEK 31.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -0.12 |
| Gross Margin | -1.51% |
| Net Profit Margin | -508.73% |
| Debt/Equity Ratio | 37.5% |
How did M02 perform over the long term?
See historical performance and comparison